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Abstract
Background: Studies in bipolar disorder (BD) to date are limited in their ability to provide a whole-disease
perspective - their scope has generally been confined to a single disease phase and/or a specific treatment.
Moreover, most clinical trials have focused on the manic phase of disease, and not on depression, which is
associated with the greatest disease burden. There are few longitudinal studies covering both types of patients
with BD (I and II) and the whole course of the disease, regardless of patients’ symptomatology. Therefore, the Wide
AmbispectiVE study of the clinical management and burden of Bipolar Disorder (WAVE-bd) (NCT01062607) aims to
provide reliable information on the management of patients with BD in daily clinical practice. It also seeks to
determine factors influencing clinical outcomes and resource use in relation to the management of BD.
Methods: WAVE-bd is a multinational, multicentre, non-interventional, longitudinal study. Approximately 3000 patients
diagnosed with BD type I or II with at least one mood event in the preceding 12 months were recruited at centres in
Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine and Venezuela. Site selection methodology
aimed to provide a balanced cross-section of patients cared for by different types of providers of medical aid (e.g.
academic hospitals, private practices) in each country. Target recruitment percentages were derived either from scientific
publications or from expert panels in each participating country. The minimum follow-up period will be 12 months, with
a maximum of 27 months, taking into account the retrospective and the prospective parts of the study. Data on
demographics, diagnosis, medical history, clinical management, clinical and functional outcomes (CGI-BP and FAST scales),
adherence to treatment (DAI-10 scale and Medication Possession Ratio), quality of life (EQ-5D scale), healthcare resources,
and caregiver burden (BAS scale) will be collected. Descriptive analysis with common statistics will be performed.
Discussion: This study will provide detailed descriptions of the management of BD in different countries,
particularly in terms of clinical outcomes and resources used. Thus, it should provide psychiatrists with reliable and
up-to-date information about those factors associated with different management patterns of BD.
Trial registration no: ClinicalTrials.gov: NCT01062607
Background
Bipolar disorder (BD) is not just a single disorder, but a
category of lifelong mood disorders characterised by the
presence of one or more recurrent manic, hypomanic
and depressive episodes. Individuals who experience
manic episodes also commonly experience depressive
episodes or symptoms, or mixed episodes in which fea-
tures of both mania and depression are present. While
these episodes are usually separated by periods of normal
mood, in some patients depression and mania may
rapidly alternate [1].
Estimates for lifetime prevalence of any type of BD range
from 0.5% to 5%. However, caution must be used when
comparing studies, as the diagnostic assessment methods
and criteria used to formulate diagnoses vary from study
to study [2]. A recent review of epidemiological studies,
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which aimed to determine the prevalence of BD in Europe,
revealed a remarkable degree of consistency across diverse
study designs and between countries. The lifetime preva-
lence rate of mania (BD type I) appears to be very similar
across studies, with estimates ranging from 0.1-0.2% to
1.8%. There is reasonably consistent evidence that BD-I
and BD-II disorders, diagnosed according to criteria in the
fourth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) [1], have an estimated 1-year
prevalence of approximately 1%, with no major differences
by age group and gender [3].
Over 90% of patients with BD experience recurrences
during their lifetime [4], often within 2 years of the initial
episode, and the consequences of recurrent illness are sub-
stantial for patients. Most randomised controlled trials
investigating the efficacy of guideline-based treatment
with current drug therapies, or with new emerging thera-
pies, have assessed recurrence in patients who had initially
recovered from a mood episode. A further need is to iden-
tify the association between patient characteristics and
clinical characteristics as predictors of recurrence. This
information may allow clinicians to better understand the
course of the disease, and to focus on clinical management
of those factors with a significant impact on disease
outcomes [5].
The emerging picture of the course of BD is quite het-
erogeneous and includes slow or incomplete recovery
from acute episodes, continued risk of recurrences, and
sustained morbidity over time, even with continuous long-
term use of current treatments. Recovery from an acute
episode of mania, even if treatment is established very
early in the course of the disorder, may require 3-6 months
and thus may no longer meet the standard diagnostic cri-
teria for an acute episode (syndromal remission). Achiev-
ing symptomatic remission, defined as the presence of
minimal symptoms, may take longer and an 2 additional
months may be needed to attain the start of recovery,
defined as a sustained remission. Time to remission is
even longer following repeated recurrences of BD [6].
Moreover, BD can adversely affect the individual, redu-
cing health-related quality of life and functioning, includ-
ing employment and productivity at work [7]. It is
becoming increasingly recognised that BD is associated
with a higher level of functional impairment than pre-
viously thought, particularly with regard to social adjust-
ment and vocational functioning [6,7].
In addition to patient burden, caregiver burden is cur-
rently one of the key factors in managing patients with
BD. The term “caregiver burden” refers to the emotional,
social, and financial stresses that caring for a relative or
friend with mental illness imposes on the caregiver, and
is defined as “the presence of problems, difficulties or
adverse events which affect the life of psychiatric patient’s
caregivers” [8]. On the basis of the method established by
Pollak and Perlik [9] the primary caregiver is defined as
the family member, friend or significant other who satis-
fied the greatest number (and at least three) of five
criteria, namely: a spouse, parent or spouse equivalent;
has the most frequent contact with the patient; helps to
support the patient financially; has been the most fre-
quent collateral participant in the patient’s treatment;
and is the person contacted by treatment staff in case of
emergency.
While caregivers can accept some of the burden for the
care of patients with BD, management of the disease also
places a substantial burden on healthcare providers. BD
typically places greater demand on hospital psychiatric ser-
vices than non-BD depression [10]. A study that permits
comparison of different healthcare practices between
countries may help to optimise resource utilisation.
One of the key challenges in ensuring that a new study
produces meaningful data is to avoid any selection bias in
recruitment of both investigators and patients. This can
be achieved by having as few exclusion criteria as possi-
ble. A further challenge is to recruit patients without
contravening the diverse range of laws, which vary within
and between countries, covering privacy relating to the
acquisition and use of medical data. A recent study in
another area of medicine has attempted to avoid investi-
gator bias in patient selection by engaging a third party
to manage patient selection and recruitment [11]. In that
study, patients were able to opt out without consulting
their physician.
In view of the above, the overall objectives of the Wide
AmbispectiVE study of the clinical management and bur-
den of Bipolar Disorder (WAVE-bd) study are: to provide
accurate and reliable information on the management of
patients with BD in conditions representative of everyday
clinical practice; to determine the clinical outcomes of
such management and the use of resources in relation to
the disease; and to establish the factors associated with
different management patterns and clinical and func-
tional outcomes.
Methods
Study design
The WAVE-bd study (NCT01062607) is a multinational,
multicentre, observational, longitudinal or cohort study
of patients diagnosed with BD type I or II with at least
one mood event in the 12 months prior to the study
start (Time 0, Figure 1).
The study comprises two different follow-up phases; one
retrospective and one prospective (ambispective design).
The retrospective phase for each patient started from the
index event, which occurred a maximum of 12 months
and minimum of 3 months before Time 0, and ended
when the patient signed the informed consent form. Infor-
mation from medical records related to the patient and
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their disease during that period (i.e. retrospective informa-
tion - from index event to inclusion) was recorded in the
electronic case report form (eCRF) at the inclusion visit.
The prospective phase started when the first patient signed
the informed consent form and will end when the last
patient included in the study attends their final visit. Data
for prospective analysis are collected as described at all
visits (including the inclusion visit). All throughout the
prospective phase, the required information will be
recorded in the eCRF and the questionnaires completed
every time the patient attends the psychiatrist’s office
(unless otherwise stated). The psychiatrist will schedule
visits according to real-life clinical practice. No interven-
tions, extra procedures, or extra visits will be required for
the purpose of the study.
The study design means that patients will spend variable
amounts of time in the study depending on the date of
signing the informed consent form, the length of the
enrolment period, and the date of their index episode. The
minimum time in the study is 12 months and the maxi-
mum 27 months, considering the retrospective and pro-
spective phases, and the 6 month enrolment period
together (Figure 1).
Study population
One aim of the study is to determine how patients with
BD are managed in different settings and countries
(Austria, Belgium, Brazil, France, Germany, Portugal,
Romania, Turkey, Ukraine and Venezuela). It is there-
fore important to obtain a patient population that is
representative of real-world practice. The inclusion of
sites and patients was determined on that basis.
Sites and investigators
Since the type of site is a variable that might influence
the management of patients with BD and the profile of
patients attending each type of site may be different, it
was necessary to select different types of sites to obtain
a representative sample. Generally, patients with BD are
seen in mental health centres, clinics, private settings,
hospitals or specialised units. Since this distribution
varies from one country to another, the study centre
selection process had to be adapted locally.
Selection of participating sites was based on the per-
centage of patients that attend different types of sites in
each country, thus ensuring that patients attending one
specific site type are not over-represented in the study
sample (Table 1). These percentages were obtained
either from the literature or from expert panels from
each participating country.
The number of participating investigators is sufficient
to ensure: 1) that there is a representative sample of the
whole psychiatrist population in each country; and 2)
inclusion of a sufficient number of patients to provide
the required sample size calculated for the study. No
other criteria were applied to selection and inclusion of
investigators, in order to avoid any selection bias.
Approximately 250 study centres in 10 countries are
participating in the study. Based on the criteria
described above, target percentages of patients recruited
by each type of study centre were devised to reflect
management practices in each of the participating coun-
tries (Table 1). The study data will be able to provide a
global perspective on comparisons between public vs
private care, academic hospital vs standard hospital care,
and hospital vs non-hospital care.
Patient population
Each investigator identified all patients with at least one
mood event in the 12 months prior to the beginning of
the study (Time 0), except for those whose index mood
event occurred in the 3 months before the study start.
The aim of the study is to achieve systematic inclusion
of patients, therefore, where possible, every eligible
patient identified at each of the study centres was
invited to participate. The main exceptions were at
those sites that saw a high number of eligible patients
during the recruitment period. At these sites, investiga-
tors were allowed to recruit a representative sample
using an electronic application, which makes selections
by simple randomisation, in order to avoid any type of
selection bias.
Retrospective phase
Time 0 – the time when the patient signed the informed consent form
Inclusion
Time 0
Follow-up
12 months 6 months 9 months
Figure 1 Study design.
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Patients aged ≥ 18 years, with a diagnosis of BD type I
or II (DSM-IV-TR [1]) in any phase of the disorder and
who had at least one mood event (depression, mania,
hypomania or mixed) according to the DSM-IV-TR defi-
nitions during the 12 months prior to the beginning of
the study were eligible for recruitment, except for those
starting the index mood event less than 3 months before
Time 0, subject to their providing informed consent.
However, those patients starting the index mood event
more than 3-months before Time 0 were eligible even if
the index event was not resolved, or if the index event
had resolved and they subsequently initiated another
event.
Patients not eligible to participate in the study were
those participating in an interventional clinical study
and any patients unable to complete Patient Reported
Outcomes questionnaires.
Measurements
The WAVE-bd study aims to provide a wide-ranging pic-
ture of BD management practices, and impact on
patients, caregivers and healthcare resource use across a
range of countries. For this reason, several measuring
instruments are being employed to maximise the types of
data collected. All instruments have been validated before
the study start, including linguistic validation where
needed. In all cases, the scales were also psychometrically
validated, at least in the original language. Information
regarding demographics (sex, race, age, educational level,
professional status, degree of disability, degree of inde-
pendence or co-residence), alcohol and other substance
abuse, medical history, disease characteristics (date of
first diagnosis, type of BD, family history of psychiatric
diseases, episodes during the last 12 months, presence of
psychotic symptoms, hospital admissions, and suicide
attempts), treatments received (drug, schedule and dose,
and whether the patient received psychologist or group
therapy), healthcare resources use, and clinical outcomes
will be collected throughout the study (Table 2).
An electronic adaptation of the National Institute of
Mental Health prospective Life Chart Methodology
(NIMH-LCM™) will be used specifically for assessing
clinical outcomes during both the retrospective and the
prospective phases of the study. It allows the daily assess-
ment of mood and episode severity, based on the degree
of mood-associated functional impairment. The NIMH-
LCM provides a visual method of tracking the patient’s
mood at each visit. Each form covers a 1-month period,
Table 1 Patient recruitment by country and type of study centre
Country Site type Patients per site type (%) Total patients enrolled
Austria University hospital 16 20
Private practice 65 81
General hospital 19 24
Belgium Clinics 46 190
Private practice 31 129
General practitioner 23 95
Brazil Public hospital 88 146
University hospital 12 20
France Hospital/clinics 49 247
Private practice 51 260
Germany University hospital 27 59
Community hospital 21 46
Private practice 52 114
Portugal Hospital 24 123
Private practice 57 295
Mental health clinic 19 98
Romania Ambulatory 37 68
Hospitals 63 115
Turkey Private practice 39 151
University hospital 42 162
State hospital 18 70
Ukraine Mental health clinic 90 199
Private practice 10 22
Venezuela Private practice 33 76
Public hospital 67 155
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and clinicians rate both mania and depression on the
chart, list the medications taken by the patient during the
month, and record any other non-mood symptoms (pro-
spective phase only), if applicable [12].
During the prospective phase of the study the follow-
ing assessments will be performed to evaluate clinical
outcomes, adherence to treatment, quality of life, patient
functioning and caregiver burden:
CGI-BP scale: this is an adaptation of the Clinical
Global Impressions (CGI) scale designed to assess global
illness severity and change in patients with BD. It con-
tains nine items [13].
DAI-10 scale: the Drug Attitude Inventory (DAI) is a
self-applied scale to measure subjective responses to
medication. This instrument reveals whether the patient
is satisfied with their treatment and evaluates their
understanding of how the treatment is affecting them.
The reduced version ‘DAI-10’ has ten highly specific
items of subjective experience. These are based on the
true recorded and transcribed accounts of patients, and
response options are true/false only. These items were
selected for their capacity to discriminate between medi-
cation adherence grades in a way that can be analysed
statistically. Although the DAI is specific for schizophre-
nia, it has also been used to investigate treatment adher-
ence in patients with BD [14].
MPR: the Medication Possession Ratio (MPR), first
described by Sclar et al [15], is a formula used to deter-
mine adherence measured from the first to the last pre-
scription, with the denominator being the duration from
index to the exhaustion of the last prescription and the
numerator being the days supplied over that period
from first to last prescription. The MPR will also be
used for the retrospective phase of the study.
EQ-5D questionnaire: this is a standardised instrument
used to measure health outcomes [16]. It is applicable to
a wide range of health conditions and treatments, and it
provides a simple descriptive profile and a single index
value for health status. The respondent is asked to indi-
cate their health state by marking the box against the
most appropriate statement in each of the five dimen-
sions. This decision results in a one-digit number expres-
sing the level selected for each dimension. The digits for
five dimensions can be combined in a five-digit number
describing the respondent’s health state. It should be
noted that the numerals 1-3 have no arithmetic proper-
ties and should not be used as a cardinal score.
FAST scale: the Functioning Assessment Short Test
(FAST) is a brief instrument designed to assess the main
functional problems experienced by psychiatric patients,
particularly bipolar patients. It comprises 24 items that
assess impairment or disability in six specific function
domains: autonomy, occupational functioning, cognitive
functioning, financial issues, interpersonal relationships
and leisure time. The total score across all domains will
be measured [17].
BAS: The Burden Assessment Scale (BAS) was developed
by Reinhard and Horwitz [18] and will be assessed once
during the study. The questionnaire contains 19 items that
capture both objective and subjective consequences of pro-
viding ongoing care to the seriously mentally ill. The scale
distinguishes burden from the measurement of the ill rela-
tive’s disruptive behaviours and the family’s care-giving
activities. These are viewed as predictors rather than
aspects of burden [18].
Statistical analyses
Descriptive statistics will include frequency tables (n,
mean, median, standard deviation, minimum and maxi-
mum for continuous variables and n, frequency and per-
centage for categorical values). For the population
estimation of the variables, the two-sided 95% confi-
dence interval will be obtained.
In order to assess the association of patient characteris-
tics (including functioning and quality of life status) and
clinical management (an independent variable) with clini-
cal outcome variables (clinical evolution, mood events,
treatment-related events, suicide attempts, variation in
scales), logistic and general linear models have been
planned. Interest will focus separately on the manage-
ment differences between the models or groups of mod-
els. Model-based point estimates of odds ratios and
corresponding 95% confidence intervals will be reported.
P-values will be reported for the comparison between dif-
ferent treatments. Since visit-by-visit information from
the study index event is being collected, there will be
Table 2 Study plan and assessments
Time First
visit*
Each other
visit
Last
visit
Site information X
Patient demographics X
Medical history X
Disease characteristics X
Treatment information X X X
Healthcare resources
consumption
X X X
Clinical outcomes X X X
Adherence to treatment X X X
Quality of life X X X
Functioning X X X
Caregiver demographics X**
Caregiver burden X**
* First visit: the visit when the patient signs the informed consent form.
** If the caregiver does not attend this visit, the information will be collected
at the next visit that the caregiver attends. This information will be collected
(if the caregiver consents) only once during the study period for each
caregiver. In the event that the caregiver does not attend any visits, this
information will not be collected.
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data on patient status during the whole study period.
Therefore, it will be possible to analyse data, relative to
the time of mood event initiation.
Cox models for survival outcomes, and mixed models
for longitudinal data using country as indicator vari-
ables, adjusted for age and gender, have been planned in
order to investigate differences in clinical outcomes and
related factors between countries. A descriptive analysis
has been planned to assess factors related to consump-
tion of healthcare resources and caregiver burden,
according to caregiver-reported outcomes.
Sample size
The sample size was calculated in order to ensure that the
study obtains meaningful data for descriptive purposes of
general clinical management and clinical outcomes at a
country level. The main outcome used in the sample size
calculation was the proportion of episodes in 1.5 years and
the goal was to estimate this proportion in the study popu-
lation. The minimum number of patients required was
estimated, based on an expected proportion of patients
with episodes in one year of 35%, assuming an alpha =
0.05, power = 0.80 and a precision of 0.05 (with a 95%
confidence interval). The estimated sample size was 370
patients per country (or 400 if it is assumed that approxi-
mately 10% will be lost to follow up). Fewer patients per
country would provide information on the proportion of
episodes with a precision less 5%. It was estimated that
approximately 3,200 patients across different countries
would be included in the study, but that this number
might vary depending on the number of participating
countries and sample size in each.
Safety
The non-interventional nature of this study means that
safety data will not be collected proactively. However,
spontaneously reported safety events will be communi-
cated to the appropriate health authority, as required by
post-marketing pharmacovigilance regulations.
Study ethics and patient confidentiality
The study will be performed in accordance with ethical
principles that are consistent with the Declaration of Hel-
sinki 2008 revision of the International Conference on
Harmonisation - Good Clinical Practice (ICH GCP) guide-
lines and the applicable legislation on non-interventional
studies.
The study protocol and informed consent form were
approved in writing by the relevant ethics committees in
each participating country, as follows: Austria; EC of Salz-
burg: Belgium; Comité d’Ethique, CUB Hôpital Erasme;
Ethische Commissie, vzw Gezondheidszorg Oostkust;
Comité d’Ethique, Hôpital Saint Joseph; Comité d’Ethique
Hospitalier/HPBV, Hôpital Psychiatrique du Beau Vallon;
Comité d’Ethique OM045, Clinique St.-Pierre; Comité
d’Ethique Hospitalier-Facultaire Universitaire de Liège,
Centre Hospitalier Universitaire du Sart Tilman; Ethische
Commissie/Coördinator klinische studies, AZ Sint-Lucas
Brugge; Commissie voor Medische Ethiek, Psychiatrisch
Zkh. Onze Lieve Vrouw; Comité d’Ethique, Cliniques Uni-
versitaires UCL de Mont-Godinne; Commissie Medische
Ethiek - Toetsingscommissie, Campus Gasthuisberg;
Comité d’Ethique, U.C.L. - Faculté de Médecine; Commis-
sie voor Ethiek, AZ St.-Jan Brugge; Comité d’Ethique, C.H.
P. Petit Bourgogne; Toetsingscommissie Ethiek GGZ
Broeders van Liefde, U.P.C. Sint-Kamillus; Comité d’Ethi-
que, C.H.P. Les Marronniers; Secrétariat du Comité d’Ethi-
que ISPPC, CHU A. Vésale; Comité d’Ethique, CUB
Hôpital Erasme; Comité d’Ethique, Vivalia Centre Univer-
sitaire Provincial La Clairière: Brazil; Comissão Nacional
de Ética em Pesquisa; Comitê de Ética em Pesquisa da
Maternidade Climério de Oliveira; Comitê de Ética em
Pesquisa do Hospital Irmãos Penteado - Irmandade de
Misericórdia de Campinas; Comissão de Ética para Análise
de Projetos de Pesquisa - CAPPesq da Diretoria Clínica do
Hospital das Clínicas e da Faculdade de Medicina da USP;
Comitê de Ética em Pesquisa da Faculdade de Medicina
de Botucatu; Comitê de Ética em Pesquisa da Universidade
Federal de Goiás (CEPHMA/HC/UFG); Comitê de Ética
em Pesquisa do Hospital Pró-Cardíaco; Comitê de Ética
em Pesquisa da Secretaria de Estado da Saúde de Santa
Catarina - CEP-SES/SC; Comite de Ética em Pesquisa da
Faculdade de Medicina do ABC: France: IEC of of Ile de
France VI; Doctors Governing Body: Germany; Ethikkom-
mission.Ernst-Moritz Arndt Universität Greifswald: Portu-
gal; Data Privacy Authority (Comissão Nacional de
Protecção de Dados); Comissão de Ética para a Saúde;
Comissão de Ética do Hospital dos Lusíadas; Comissão de
Ética da Clínica Psiquiátrica de S. José; Comissão de Ética
do Hospital de Magalhães Lemos, EPE; Comissão de Ética
da Saúde do Hospital de São João; Comissão de Ética do
Hospital Infante D. Pedro EPE; Comissão de Ética do Cen-
tro Hospitalar Médio Tejo, EPE; Comissão de Ética do
Centro Hospitalar de Setúbal, EPE: Romania; National
Drug & Medical Devices Agency; National Ethics Com-
mittee: Turkey; Central IRB within MoH: Ukraine; Central
Ethics Committee of Ministry of Health of Ukraine: Vene-
zuela; RA: Instituto Nacional de Higiene “Rafael Rangel";
Comité de Bioética Hospital Universitario de Caracas;
Centro Nacional de Bioética de Venezuela; Instituto
Autónomo Hospital Universitario de Los Andes; Comisión
de Ética del Hospital Vargas.
Investigators will perform the study in accordance with
the regulations and guidelines governing medical practice
and ethics in their country and in accordance with cur-
rently acceptable techniques. Patients and caregivers will
authorise the collection, use and disclosure of their per-
sonal data by the investigator and by those persons who
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need that information for the purposes of the study.
Study data will be stored in a computer database, main-
taining confidentiality in accordance with local laws for
data protection.
Discussion and conclusions
Current treatment guidelines for BD are based on the
results of published randomised clinical trials and meta-
analyses. Although these methods are the most reliable
sources of evidence, they also have limitations arising
from restricted study populations. Many studies may
lack external validity due to strict inclusion criteria,
which usually do not allow the inclusion of patients
with severe disease or those with co-morbidities such as
alcohol and drug dependence, or anxiety disorders that
are highly prevalent among patients with BD.
Very few longitudinal observational studies carried out
to date have studied BD from a comprehensive perspec-
tive, i.e. providing a global perspective of a representative
sample of patients and simultaneously considering all
phases of the disease. Most have focused on only one of
the phases, either manic or depressive, or have researched
patients who were attending tertiary settings only or
receiving certain specific treatments [19-22].
The complex nature of bipolar illness may complicate
the measurement of impairment. In addition to other
potential determinants of functional impairment in BD,
cognitive impairment may be an important factor. Most
patients with BD consistently show evidence of impair-
ments in executive functioning, attention, verbal and
working memory, and tests of visuospatial function.
Recent studies in currently euthymic patients with BD
suggest that such deficits can persist even after apparent
clinical recovery, and so cannot be entirely ascribed to
acute, state-related cognitive deficits that are well known
to occur in acute episodes of emotional disease [6]. The
impact of these cognitive deficits on functioning is
remarkable [23,24].
To date, few studies have investigated the care-giving
stresses and the associated health and mental health risks
among the family and friends of patients with BD [25-27].
Results from these studies reveal that up to 93% of care-
givers of bipolar patients suffer from a moderate or higher
level of stress when the patient is admitted to an inpatient
unit or outpatient clinic; moreover, 70% of caregivers still
report a moderate-to-high burden 15 months after patient
admission. Higher levels of caregiver burden at the time of
patient admission were associated with increased depres-
sion and use of mental health services by caregivers during
the previous 7 months. Poorer social and occupational
functioning, an episode in the last 2 years, history of rapid
cycling, and the caregiver being responsible for medication
intake explained a quarter of the variance of the caregiver’s
subjective burden in a landmark study [28].
The large, non-interventional WAVE-bd study is
expected to provide a comprehensive comparison of the
routine management of patients with BD across differ-
ent countries, particularly in terms of clinical outcomes
and resources used, and to determine the consequences
of such management. A key consideration is whether
the study population is truly representative of the overall
population of patients with BD. Inclusion of patients
was based on random selection from the whole BD
population recorded by each investigator. This metho-
dology, added to the large sample size, ensures that the
number of patients of each type is representative of the
actual population diagnosed in real life.
Since WAVE-bd is a multinational study, it is possi-
ble that application of diagnostic criteria will vary
slightly between regions and countries and some
patients, especially those with type II BD who could
have been included, will be given a different diagnosis
and managed for major depressive disorder or even
schizophrenia, rather than BD. However, inclusion of
misdiagnosed patients would introduce bias, since the
main objective of this study is to evaluate treatment
practices for BD.
All of the studies described above were based on low
rates of recruitment from the eligible population. A total
of 3188 randomly selected patients were invited to parti-
cipate in the WAVE-bd study. Of these, 2965 (93%)
accepted the invitation to participate and provided writ-
ten informed consent. The other 7% of patients screened
declined to participate and will not be included in the
analysis. The systematic approach to inclusion of
patients in the WAVE-bd study and stratification by
type of study centre to reflect local practice, combined
with the 93% patient acceptance rate, leads us to believe
that the study population avoids selection bias and is
truly representative of the overall global population with
unstable BD. Consequently, the investigators believe that
the study promises to provide psychiatrists with reliable
and up-to-date information about the factors associated
with different management patterns of BD on a global
scale.
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